OncoMatch/Clinical Trials/NCT06050317
Sintilimab Combined With Chemotherapy and Radiotherapy in Patients With Inoperable Pancreatic Cancer
Is NCT06050317 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Sintilimab Plus mFFN or NALIRIFOX and Radiation for pancreas cancer.
Treatment: Sintilimab Plus mFFN or NALIRIFOX and Radiation — Hypothesis: Survival benefits could be found in Sintilimab plus chemotherapy and radiotherapy in patients with inoperable pancreatic cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Pancreatic Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: anti-PD-1/PD-L1/PD-L2 or co-inhibitory T-cell receptor therapy
previously received anti-PD-1, anti-PD-L1, or anti-PD-L2 drugs or another drug that stimulates or synergistically inhibits T-cell receptors
Cannot have received: systemic anti-tumor therapy
patients who have not received systemic anti-tumor therapy
Cannot have received: Chinese patent medicines with anti-tumor indications or drugs with immunomodulatory effects
systemic treatment with Chinese patent medicines with anti-tumor indications or drugs with immunomodulatory effects within two weeks before enrollment
Lab requirements
Blood counts
ANC ≥ 1.0 × 10^9 cells/L, platelets ≥ 75 × 10^9 cells/L, hemoglobin ≥ 9.0 g/dl
Kidney function
creatinine ≤ 1.5 × ULN
Liver function
AST < 2.5 × ULN, ALT < 2.5 × ULN, total bilirubin ≤ 1.5 × ULN
Blood routine examination: Absolute neutrophil count (ANC) ≥ 1.0 ×109 cells/L, platelets ≥ 75×109 cells/L, hemoglobin ≥ 9.0 g/dl; AST<2.5 × ULN, ALT<2.5 × ULN, creatinine ≤1.5xULN, total bilirubin ≤1.5 X ULN.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify